Article
Oncology
Simon Garinet, Pascal Wang, Audrey Mansuet-Lupo, Ludovic Fournel, Marie Wislez, Helene Blons
Summary: This review discusses the need for improved risk assessment and patient selection for adjuvant and neoadjuvant chemotherapy following resected lung cancer. The current evaluation of recurrence risk is primarily based on TNM classification, but more than 25% of early-stage patients still experience relapse. Validated prognostic and theranostic markers are needed to better stratify patients and guide adjuvant therapies in resected lung cancer.
Article
Biology
Pengfei Xu, Haoze Yu, Kuo-Chang Tseng, Mackenzie Flath, Peter Fabian, Neil Segil, J. Gage Crump
Summary: The specification of cartilage relies on Sox9, but how transcription factors like Sox9 gain access to cartilage-specific regulatory regions during skeletal development was unknown. By analyzing chromatin accessibility in zebrafish chondrocytes, it was found that Foxc1 promotes chondrogenesis by establishing chromatin accessibility at cartilage-associated enhancers, with a decrease in accessibility leading to loss of dorsal facial cartilages. These findings highlight the dynamic establishment of cartilage-associated chromatin accessibility and the role of Foxc1 in promoting chondrogenesis in the face.
Article
Oncology
Xiuming Huang, Mingfang Huang, Minbiao Chen, Xianshan Chen
Summary: SLC9A3-AS1 is upregulated in NSCLC and inhibits NSCLC progression by targeting miR-760. This suggests that SLC9A3-AS1 may serve as a novel biomarker and therapeutic target for NSCLC.
CANCER MANAGEMENT AND RESEARCH
(2022)
Review
Oncology
Yan-qing Wang, Xu-dong Liu, Wen-liang Bai, Shan-qing Li
Summary: The study aimed to evaluate factors affecting the survival of N2 NSCLC patients who undergo surgical resection and define resectable N2 based on survival benefits. Male gender, old age, high T stage and grade, adenosquamous and squamous cell carcinoma, among other factors, were identified as independent risk factors for higher mortality. The nomogram developed in the study showed satisfactory consistency between predicted and actual survival status, providing a useful tool for clinical decision-making for this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Feifei Li, Zhitong Bing, Weiqiang Chen, Fei Ye, Yan Liu, Lan Ding, Xiaodong Jin
Summary: Radiotherapy plays a major role in NSCLC treatment, but radioresistance affects the curative efficacy of advanced NSCLC. Proteomic analysis identified up-regulated proteins like CRIP2, ARHGDIB, and PADI3 in radioresistant cells. These proteins may serve as potential biomarkers for diagnosis and prognosis prediction, affecting X-ray radiosensitivity of NSCLC through regulating apoptosis and cell cycle arrest.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Cell Biology
Jiangtao You, Qingshi Wang, Longlong Cong, Rui Zhao, Wei Cui, Huan Chen
Summary: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for about 85% of all cases. The study revealed that RASA1 gene mutations in squamous cell carcinoma were associated with better prognosis and immune features, and hsa-miR-23a was significantly correlated with survival in RASA1 mutation samples, suggesting the presence of specific ceRNAs in mutation-specific subgroups in NSCLC.
Article
Pathology
Qi Qi, Chen Chen, Chang Liu, Bin Zhang, Yuchen Ma, Hua Zhang, Wuhao Huang, Changli Wang
Summary: The study demonstrated that linc8087 is downregulated in NSCLC and is significantly associated with poor survival. Overexpression of linc8087 inhibits cell migration and invasion, while its knockdown promotes cell migration and invasion. The findings suggest that linc8087 plays a key role in NSCLC progression and may serve as a meaningful prognostic biomarker and potential therapeutic target.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Wei Dong, Congjie Wang, Chunsheng Wang, Kewei Zhao, Zhao Ma, Shanliang Hu
Summary: This study aimed to investigate the clinicopathological features, treatment response, and survival outcomes of patients with uncommon EGFR mutations (um-EGFRms) following afatinib treatment. It was found that patients with a single um-EGFRm were more likely to have a favorable treatment response and prognosis after afatinib treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jiajin Chen, Yunjie Song, Yi Li, Yongyue Wei, Sipeng Shen, Yang Zhao, Dongfang You, Li Su, Maria Moksnes Bjaanaes, Anna Karlsson, Maria Planck, Johan Staaf, Aslaug Helland, Manel Esteller, Hongbing Shen, David C. C. Christiani, Ruyang Zhang, Feng Chen
Summary: This study identified significant gene-gene interactions associated with non-small-cell lung cancer survival through a three-step analytic strategy. Two interactions were found at both the epigenetic and transcriptional levels, providing potential clues for precision treatment of NSCLC.
MOLECULAR ONCOLOGY
(2023)
Article
Immunology
Song Guan, Shufeng Zhang, Kai Ren, Xingyue Li, Xue Li, Lujun Zhao
Summary: This study retrospectively analyzed the efficacy and safety of induction chemoimmunotherapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) receiving chemoradiotherapy (CRT). The study found that induction chemoimmunotherapy improved progression-free survival and showed better treatment response and survival outcomes in patients receiving concurrent chemoradiotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Genetics & Heredity
Zhaojin Li, Yu Cui, Shupeng Zhang, Jie Xu, Jianping Shao, Hekai Chen, Jingzhao Chen, Shun Wang, Meizhai Zeng, Hao Zhang, Siqian Lu, Zhi Rong Qian, Guoqiang Xing
Summary: This study explores the association between hypoxia-related genes (HRGs) and prognosis, tumor microenvironment characteristics, and therapeutic response in NSCLC patients. By analyzing data from the TCGA and GEO databases, a prognostic model consisting of nine HRGs was developed, which showed promising predictive power for survival and recurrence risk in NSCLC patients.
FRONTIERS IN GENETICS
(2023)
Article
Immunology
Guan Zhang, Aqing Liu, Yanjie Yang, Ying Xia, Wentao Li, Yunhe Liu, Jing Zhang, Qian Cui, Dong Wang, Xu Liu, Yongtie Guo, Huayu Chen, Jianchun Yu
Summary: In advanced non-small cell lung cancer patients, there is a lack of sensitive prognostic biomarkers to identify those who will benefit from treatment. A study found that higher levels of certain T cell subsets, such as CD4(+) Tn and CD4(+) Tscm, were associated with longer progression-free survival, indicating their potential as prognostic markers. Higher absolute counts of these T cell subsets also correlated with better response to immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Can Tan, Pieter R. Norden, Wei Yu, Ting Liu, Naoto Ujiie, Sun Kyong Lee, Xiaocai Yan, Yaryna Dyakiv, Kazushi Aoto, Sagrario Ortega, Isabelle G. De Plaen, Venkatesh Sampath, Tsutomu Kume
Summary: FOXC1 and FOXC2 play vital roles in intestinal regeneration by stimulating CXCL12 and Wnt signaling pathways. Deletion of Foxc1, Foxc2, or both results in defects in vascular regrowth, reduced expression of CXCL12 and RSPO3 in blood endothelial cells and lymphatic endothelial cells respectively, and increased activation of Wnt signaling in intestinal stem cells. Treatment with CXCL12 and RSPO3 rescues the intestinal damage induced by ischemia-reperfusion injury in mutant mice.
Article
Biochemical Research Methods
Kaikai Shen, Yuqing Wei, Tangfeng Lv, Yong Song, Xiaogan Jiang, Zhiwei Lu, Ping Zhan, Xianghai Wang, Meng Fan, Weihua Lu
Summary: JAK1 overexpression is associated with better prognosis and immune infiltration in non-small cell lung cancer (NSCLC).
BMC BIOINFORMATICS
(2021)
Article
Oncology
Huanxi Wang, Xizi Jiang, Yu Cheng, Hongjiu Ren, Yujiao Hu, Yao Zhang, Hongbo Su, Zifang Zou, Qiongzi Wang, Zongang Liu, Jiameng Zhang, Xueshan Qiu
Summary: This study demonstrated that MZT2A promotes proliferation and invasion in NSCLC by activating LGALS3BP and Akt. The upregulation of MZT2A was associated with poor prognosis in NSCLC, indicating its potential as a biomarker or therapeutic target for controlling NSCLC progression.
